Palvella Therapeutics, Inc. Common Stock
$150.56
-$3.76 (-2.44%)
$149.20Day Range$154.72
Key Statistics
Market Cap
$2.17B
Shares Outstanding
14.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 16, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$154.72
Day High
$154.72
Day Low
$149.20
Volume
646.5K
VWAP
$150.86
Prev Close
$154.32
Transactions
--
Acc. Volume
--
About Palvella Therapeutics, Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
PHARMACEUTICAL PREPARATIONSSIC 283429 employees353 W. LANCASTER AVENUE, WAYNE, PA, 19087(484) 253-1461IPO Dec 16, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001583648
- Composite FIGI
- BBG0055C3N57
- Share Class FIGI
- BBG0055C3N66
- Ticker Root
- PVLA
- SIC Code
- 2834
About Palvella Therapeutics, Inc. Common Stock (PVLA) Stock
Palvella Therapeutics, Inc. Common Stock (PVLA) closed the 2026-09-18 session at $150.56, down 2.44% versus the previous close (-3.76). The stock opened at $154.72 and traded between $149.20 and $154.72 during that session. Session trading volume was 646K shares. The volume-weighted average price (VWAP) is $150.86.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Palvella Therapeutics, Inc. Common Stock has a market capitalization of $2.17 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PVLA is listed on the XNAS exchange. The company employs approximately 29 people. Palvella Therapeutics, Inc. Common Stock is headquartered in WAYNE, PA. The recorded listing date is 2024-12-16.
On this page you can find market PVLA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.